Dr. Clay Siegall Ph.D. is the co- founder and CEO of Seattle Genetics. The biotech firm that is based in Seattle and founded in 1998 is focused on developing targeted therapy drugs for various diseases that have not experienced enough mortality improvements for several years. Dr. Siegall is a scientist by profession and has several years of experience in the medical field. His impeccable leadership skills have enabled the company to develop antibody-drug conjugates (ADCs) called ADCETRIS® (brentuximab vedotin) that secured its first FDA approval in 2011. ADCETRIS was as a result of a collaboration with a company called Takeda Pharmaceutical and it has achieved global approval in over 65 countries. Seattle Genetics has also advanced a diverse pipeline of proprietary ADCs targeting the treatment of cancer.
Dr. Clay Siegall has managed to lead Seattle Genetics into entering strategic licenses for its ADC technology with Genentech (Roche), GlaxoSmithKline, and Pfizer, and thus generating over $350 million. Under his leadership, the company has acquired capital through public funding, private financing, and the company’s 2001 IPO worth over $1.2 billion.
Before joining Seattle Genetics, Dr. Clay Siegall was working with the Bristol-Myers Squibb Pharmaceutical Research Institute from and the National Cancer Institute. During that period he also honed his skills by working with the National Institutes of Health. He serves in various boards such as the Boards of Directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable. He has won awards including the Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012 and the University of Maryland Alumnus of the Year for Computer among others. He holds 15 patents and 70 publications to his name. Dr. Siegall earned a Ph.D. in Genetics from George Washington University and his B.S. in Zoology from the renown University of Maryland.